Portola Pharmaceuticals (NASDAQ:PTLA) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.
PTLA has been the subject of a number of other reports. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, May 6th. Cowen reiterated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Thursday, August 9th. Morgan Stanley reiterated an “equal weight” rating and issued a $46.00 price target (up from $31.00) on shares of Portola Pharmaceuticals in a research note on Monday, May 7th. Zacks Investment Research downgraded Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Citigroup lifted their price target on Portola Pharmaceuticals to $64.00 and gave the stock a “buy” rating in a research note on Monday, May 7th. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Portola Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $51.40.
Shares of NASDAQ PTLA opened at $26.22 on Monday. Portola Pharmaceuticals has a 1 year low of $25.50 and a 1 year high of $64.56. The stock has a market cap of $1.93 billion, a PE ratio of -5.45 and a beta of 1.76. The company has a debt-to-equity ratio of 0.91, a quick ratio of 6.59 and a current ratio of 6.69.
In other Portola Pharmaceuticals news, CEO William Lis sold 5,113 shares of Portola Pharmaceuticals stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $45.21, for a total value of $231,158.73. Following the completion of the transaction, the chief executive officer now directly owns 222,035 shares in the company, valued at $10,038,202.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of PTLA. Raymond James & Associates boosted its stake in Portola Pharmaceuticals by 72.9% in the fourth quarter. Raymond James & Associates now owns 7,900 shares of the biopharmaceutical company’s stock valued at $385,000 after acquiring an additional 3,330 shares during the period. Alps Advisors Inc. boosted its stake in Portola Pharmaceuticals by 21.0% in the first quarter. Alps Advisors Inc. now owns 87,516 shares of the biopharmaceutical company’s stock valued at $2,858,000 after acquiring an additional 15,210 shares during the period. Oppenheimer & Co. Inc. boosted its stake in Portola Pharmaceuticals by 311.8% in the first quarter. Oppenheimer & Co. Inc. now owns 21,599 shares of the biopharmaceutical company’s stock valued at $705,000 after acquiring an additional 16,354 shares during the period. Kornitzer Capital Management Inc. KS boosted its stake in Portola Pharmaceuticals by 29.5% in the first quarter. Kornitzer Capital Management Inc. KS now owns 1,069,944 shares of the biopharmaceutical company’s stock valued at $34,944,000 after acquiring an additional 243,917 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Portola Pharmaceuticals in the first quarter valued at approximately $128,000. Institutional investors own 87.09% of the company’s stock.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.